Methocarbamol
Methocarbamol is a centrally acting skeletal-muscle relaxant used for selected muscle spasm and rigidity syndromes. Veterinary applications include acute traumatic or inflammatory musculoskeletal conditions and control of tremors associated with some intoxications. Its clinical contribution is reduction of excessive muscle activity, often alongside separate treatment of pain or the underlying cause.
Group
Centrally acting skeletal muscle relaxant
Mechanism of Action
Methocarbamol depresses central polysynaptic reflex activity and reduces excessive motor output associated with muscle spasm. Its precise central molecular target is incompletely defined. It does not act primarily by blocking neuromuscular transmission or directly altering the contractile machinery of skeletal muscle. Reduced reflex-driven contraction can lessen rigidity, tremor and associated muscular strain.
Dose Rates
Dogs
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Moderate muscle spasm | 44 mg/kg | IV | Once | Give slowly to effect; reassess before any further dose. |
| Musculoskeletal spasm — Initial | 44 mg/kg | PO | Every 8 h | Up to 21 days; Oral initial regimen; maximum treatment period 14-21 days. If no response within five days, reassess rather than continuing. |
| Musculoskeletal spasm — Maintenance | 22–44 mg/kg | PO | Every 8 h | Up to 21 days; After initial response; maximum course 14-21 days. |
| Severe toxin-associated tremors | Reference only | IV | 55-220 mg/kg IV slowly to effect; maximum 330 mg/kg/day. A separate source gives up to 222 mg/kg with maximum cumulative 333 mg/kg. Retain these as distinct capped protocols, not an unrestricted calculated dose. | |
| Intervertebral disc-associated spasm | 15–20 mg/kg | PO | Every 8 h |
Cats
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Moderate muscle spasm | 44 mg/kg | IV | Once | Give slowly to effect; reassess before any further dose. |
| Musculoskeletal spasm — Initial | 44 mg/kg | PO | Every 8 h | Up to 21 days; Oral initial regimen; maximum treatment period 14-21 days. If no response within five days, reassess rather than continuing. |
| Musculoskeletal spasm — Maintenance | 22–44 mg/kg | PO | Every 8 h | Up to 21 days; After initial response; maximum course 14-21 days. |
| Severe toxin-associated tremors | Reference only | IV | 55-220 mg/kg IV slowly to effect; maximum 330 mg/kg/day. A separate source gives up to 222 mg/kg with maximum cumulative 333 mg/kg. Retain these as distinct capped protocols, not an unrestricted calculated dose. | |
| Permethrin-associated tremors | Reference only | IV | Initially 50-150 mg/kg; give half slowly over 5-10 minutes, then the remainder as needed to effect. Repeat only within total maximum 330 mg/kg/day; severe cases may require a controlled infusion. |
Horses
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Moderate muscle spasm | 4.4–22 mg/kg | IV | Every 8 h | Slowly to effect; sedation/depression increases at higher doses. |
| Severe muscle spasm | 22–55 mg/kg | IV | Every 8 h | Slowly to effect; sedation/depression increases at higher doses. |
| Acute rhabdomyolysis-associated spasm | 15–25 mg/kg | IV | Slow IV infusion; may repeat up to four times daily if needed. | |
| Oral muscle relaxation | Reference only | PO | Source describes an oral amount 2-3 times the selected IV dose; this is a protocol-dependent relation rather than one universal oral range. |
Indications
- Adjunctive treatment of skeletal-muscle spasm associated with acute inflammatory or traumatic musculoskeletal disease in dogs, cats and horses.
- Control of selected toxin-associated muscle tremors, including pyrethroid or metaldehyde intoxication in small animals.
- Adjunctive reduction of rigidity or muscle spasms in tetanus or strychnine poisoning.
Contraindications
- Injectable preparations containing polyethylene glycol are contraindicated in known or suspected renal pathology.
- Do not inject SC; avoid extravasation.
Interactions
- Other CNS depressants increase sedation.
- May oppose pyridostigmine effects in myasthenic patients.
Adverse effects
- Sedation, weakness, salivation, vomiting and ataxia.
Toxicity
Overdose causes marked CNS depression; protect the airway and provide supportive care.
Preparations
| Preparation | Form | Strength | Route |
|---|---|---|---|
| Methocarbamol injection 100 mg/mL Do not give SC; avoid in renal disease if PEG-containing. Do not freeze; inspect diluted solutions for precipitation. | Injection | 100 mg / mL | IV |
| Methocarbamol 500 mg tablet | Tablet | 500 mg / tablet | PO |
Monitoring and Administration
For 100 mg/mL injection in dogs/cats do not exceed 2 mL/minute. Titrate slowly to relaxation and avoid extravasation.
Monitor muscle relaxation, respiratory effort and alertness. Do not induce vomiting in a depressed patient.
For severe protocols, distinguish the maximum of 330 mg/kg/day from the separately described 333 mg/kg cumulative maximum. These limits belong to different regimens and must not be combined or ignored.